Broadfin Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Broadfin Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-300,000	Closed	-$4.26M	–	69
2018 Q1	$4.26M	Hold	300,000	–	–	0.66%	37
2017 Q4	$4.38M	Buy	+300,000	New	+$4.21M	0.72%	32
2017 Q3	–	Sell	-1,000,000	Closed	-$11.9M	–	56
2017 Q2	$11.9M	Hold	1,000,000	–	–	1.44%	25
2017 Q1	$14.8M	Buy	1,000,000 +200,000	+25%	+$3.24M	1.79%	20
2016 Q4	$12.9M	Sell	800,000 -250,000	-24%	-$4.53M	1.44%	20
2016 Q3	$19M	Buy	1,050,000 +550,000	+110%	+$10.7M	1.71%	16
2016 Q2	$8.23M	Sell	500,000 -1,000,000	-67%	-$16.2M	0.8%	32
2016 Q1	$24.9M	Buy	1,500,000 +1,000,000	+200%	+$17.5M	2.4%	11
2015 Q4	$10.8M	Hold	500,000	–	–	0.67%	39
2015 Q3	$9.91M	Sell	500,000 -600,000	-55%	-$19M	0.55%	48
2015 Q2	$38.2M	Buy	1,100,000 +600,000	+120%	+$18.3M	2.05%	11
2015 Q1	$13M	Buy	500,000 +200,000	+67%	+$3.67M	1.01%	22
2014 Q4	$3.87M	Buy	300,000 +298,000	+14,900%	+$3.73M	0.34%	58
2014 Q3	$450K	Buy	+2,000	New	+$23.2K	0.05%	72

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Broadfin Capital's HZNP Position: Q4 2018 in Review

Broadfin Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2018, closing a stake of 410,532 shares — an estimated $8.04M sold.

Broadfin Capital first reported a position in HZNP in Q3 2013 and held it in 21 quarters. The position peaked at $183M in Q1 2015. 239 funds tracked by Wall St. Rank hold HZNP as of Q4 2018.

Broadfin Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2018 after selling out during the quarter.
Broadfin Capital sold 410,532 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2018, an estimated $8.04M.
Broadfin Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 21 quarters.
Broadfin Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $183M in Q1 2015.
239 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2018.

Based on Broadfin Capital's 13F filing for Q4 2018, filed 14 Feb 2019.